These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18758303)

  • 1. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
    Choong NW; Mauer AM; Haraf DJ; Lester E; Hoffman PC; Kozloff M; Lin S; Dancey JE; Szeto L; Grushko T; Olopade OI; Salgia R; Vokes EE
    J Thorac Oncol; 2008 Sep; 3(9):1003-11. PubMed ID: 18758303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
    Kelly K; Chansky K; Gaspar LE; Albain KS; Jett J; Ung YC; Lau DH; Crowley JJ; Gandara DR
    J Clin Oncol; 2008 May; 26(15):2450-6. PubMed ID: 18378568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
    Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
    Sangha R; Davies AM; Lara PN; Mack PC; Beckett LA; Hesketh PJ; Lau D; Li T; Perkins N; Gandara DR
    J Thorac Oncol; 2011 Dec; 6(12):2112-9. PubMed ID: 21892109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
    Socinski MA; Blackstock AW; Bogart JA; Wang X; Munley M; Rosenman J; Gu L; Masters GA; Ungaro P; Sleeper A; Green M; Miller AA; Vokes EE
    J Clin Oncol; 2008 May; 26(15):2457-63. PubMed ID: 18487565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
    Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
    J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
    Lilenbaum R; Samuels M; Wang X; Kong FM; Jänne PA; Masters G; Katragadda S; Hodgson L; Bogart J; Bradley J; Vokes E
    J Thorac Oncol; 2015 Jan; 10(1):143-7. PubMed ID: 25384173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
    Riely GJ; Rizvi NA; Kris MG; Milton DT; Solit DB; Rosen N; Senturk E; Azzoli CG; Brahmer JR; Sirotnak FM; Seshan VE; Fogle M; Ginsberg M; Miller VA; Rudin CM
    J Clin Oncol; 2009 Jan; 27(2):264-70. PubMed ID: 19047285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
    Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
    Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
    Wozniak AJ; Moon J; Thomas CR; Kelly K; Mack PC; Gaspar LE; Raben D; Fitzgerald TJ; Pandya KJ; Gandara DR
    Clin Lung Cancer; 2015 Sep; 16(5):340-7. PubMed ID: 25703100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
    Vokes EE; Herndon JE; Kelley MJ; Cicchetti MG; Ramnath N; Neill H; Atkins JN; Watson DM; Akerley W; Green MR;
    J Clin Oncol; 2007 May; 25(13):1698-704. PubMed ID: 17404369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.